LIBERTY CORNER, N.J., Aug. 10 /PRNewswire/ -- Reliant Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of its common stock. The registration statement contemplates that Reliant will sell newly issued common stock and that certain stockholders may sell a portion of their current holdings of Reliant's common stock.
Goldman, Sachs & Co. and Merrill Lynch & Co. will act as the joint lead managers and joint book-runners for the proposed offering. The public offering will be made only by means of a prospectus which, when available, may be obtained by writing or calling one of the underwriters: Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004, Attention: Prospectus Department (Tel: 212-902-1171) or Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department (Tel: 212-449-1000).
A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reliant Pharmaceuticals, Inc.
Reliant Pharmaceuticals is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Reliant currently markets four cardiovascular products in the United States and focuses on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliant's sales force infrastructure is comprised of approximately 875 sales and marketing professionals nationwide.
|SOURCE Reliant Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved